½ÃÀ庸°í¼­
»óǰÄÚµå
1402952

¼¼°èÀÇ ¿ÏÇÏÁ¦ ½ÃÀå : ¼ºÀå, Àü¸Á, °æÀï ºÐ¼®(2024-2032³â)

Laxative Market - Growth, Future Prospects and Competitive Analysis, 2024 - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Acute Market Reports | ÆäÀÌÁö Á¤º¸: ¿µ¹® 113 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¿ÏÇÏÁ¦ ½ÃÀåÀº º¯ºñ ¹× °ü·Ã À§Àå ¹®Á¦¸¦ ¿ÏÈ­ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¿ÏÇÏÁ¦ ½ÃÀåÀº °Ç°­ ÀÎ½Ä Áõ°¡¿Í ¶óÀÌÇÁ½ºÅ¸ÀÏÀÇ º¯È­·Î ÀÎÇØ 2024-2032³âÀÇ ¿¹Ãø ±â°£ µ¿¾È ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 6.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2024-2032³â ±â°£ µ¿¾È Á¦ÇüÀÇ ¹ßÀü°ú ÀûÀÀÁõ È®´ë·Î ÀÎÇØ ½ÃÀåÀÌ °è¼Ó ÁøÈ­ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿ä¾àÇϸé, ¿ÏÇÏÁ¦ ½ÃÀåÀº °Ç°­¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, »ýȰ½À°ü º¯È­, Á¦Çü ¹ßÀü¿¡ ÈûÀÔ¾î Áö¼ÓÀûÀÎ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ºÎÀÛ¿ëÀÇ °¡´É¼ºÀº ¿©ÀüÈ÷ ¾ïÁ¦¿äÀÎÀ¸·Î ³²¾ÆÀÖ½À´Ï´Ù. ÁÖ¿ä ¾÷üµéÀº ±â¼ú Çõ½Å°ú °í°´ Á᫐ Àü·«À» ÅëÇØ °æÀï ¿ìÀ§¸¦ À¯ÁöÇϸ鼭 2023-2032³â°£ ¸ÅÃâÀÌ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

°Ç°­¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡

2023³â ¿ÏÇÏÁ¦ ½ÃÀåÀº ¼ÒºñÀÚÀÇ °Ç°­ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ Å« ÆøÀ¸·Î ¼ºÀåÇß½À´Ï´Ù. Á¡Á¡ ´õ ¸¹Àº »ç¶÷µéÀÌ Àü¹ÝÀûÀÎ °Ç°­À» À§ÇØ ±ÔÄ¢ÀûÀÎ ¹èº¯À» À¯ÁöÇÏ´Â °ÍÀÌ Áß¿äÇÏ´Ù´Â °ÍÀ» ÀνÄÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÎ½Ä Áõ°¡´Â º¯ºñ ¹× ±âŸ À§Àå ¹®Á¦¿¡ ´ëÇÑ ÇØ°áÃ¥À¸·Î ¿ÏÇÏÁ¦¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. °Ç°­¿¡ ´ëÇÑ °ü½ÉÀº 2024³âºÎÅÍ 2032³â±îÁö ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î Áö¼ÓµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶óÀÌÇÁ½ºÅ¸Àϰú ½Ä½À°üÀÇ º¯È­

¶óÀÌÇÁ½ºÅ¸Àϰú ½Ä½À°üÀÇ º¯È­µµ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¾É¾Æ¼­ »ýȰÇÏ´Â »ýȰ½À°ü°ú ½Ä½À°ü Àå¾Ö´Â º¯ºñ ¹× °ü·Ã ÁúȯÀÇ À¯º´·ü Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¿ÏÇÏÁ¦´Â Áï°¢ÀûÀÎ º¯ºñ ÇØ¼Ò¸¦ ¿øÇÏ´Â »ç¶÷µéÀ» À§ÇÑ ¼Ö·ç¼ÇÀÌ µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ¶óÀÌÇÁ ½ºÅ¸ÀÏ ¿äÀÎÀÌ Áö¼ÓµÇ¸é¼­ ¿ÏÇÏÁ¦ ¼ö¿ä´Â °è¼Ó Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç ¿¹Ãø ±â°£ µ¿¾È ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¦Á¦ÀÇ ¹ßÀü

¿ÏÇÏÁ¦ Á¦Á¦ÀÇ ¹ßÀüµµ Áß¿äÇÑ ÃËÁø¿äÀÎÀÔ´Ï´Ù. ½ÃÀåÀº ºÎÀÛ¿ëÀ» ÁÙÀÎ ´õ ºÎµå·´°í È¿°úÀûÀÎ ¿ÏÇÏÁ¦ÀÇ µµÀÔÀ» ¸ñ°ÝÇß½À´Ï´Ù. °æ±¸ ¹× Á÷Àå¿ë Á¦Á¦ÀÇ Çõ½ÅÀ¸·Î »ç¿ë°¨ÀÌ °³¼±µÇ¾î ¼ÒºñÀÚ¿¡°Ô ´õ ¸Å·ÂÀûÀÎ Á¦Á¦°¡ µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ Á¦Á¦°¡ ´õ¿í ¹ßÀüÇÔ¿¡ µû¶ó 2024³âºÎÅÍ 2032³â±îÁö ³ôÀº CAGR·Î ½ÃÀå ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿ÏÇÏÁ¦ ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ

¿ÏÇÏÁ¦ ½ÃÀåÀº ¼ºÀå¼¼¿¡µµ ºÒ±¸Çϰí ÀáÀçÀûÀÎ ºÎÀÛ¿ë¿¡ ´ëÇÑ ¿ì·Á·Î ÀÎÇØ 2023³â¿¡´Â ¿ÏÇÏÁ¦ Àå±â »ç¿ëÀ¸·Î ÀÎÇÑ ÀÇÁ¸¼º ¹× À§Àå Àå¾Ö ¹ß»ý °¡´É¼ºÀÌ ¾ïÁ¦¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ºÎÀÛ¿ëÀº 2024³âºÎÅÍ 2032³â±îÁöµµ °è¼ÓµÉ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿ÏÇÏÁ¦ÀÇ ¿Ã¹Ù¸¥ »ç¿ë¹ý¿¡ ´ëÇÑ ¼ÒºñÀÚ ±³À° ¹× ÀáÀçÀû À§Ç輺À» ÁÙÀ̱â À§ÇÑ ³ë·ÂÀÌ ÇÊ¿äÇÕ´Ï´Ù.

Åõ¿© °æ·Îº° ½ÃÀå ¼¼ºÐÈ­: °æ±¸¿ë ¿ÏÇÏÁ¦°¡ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù.

¿ÏÇÏÁ¦ ½ÃÀåÀº Åõ¿© °æ·Î¿¡ µû¶ó °æ±¸ ¹× Á÷ÀåÀÇ µÎ °¡Áö ¹üÁÖ·Î ³ª´­ ¼ö ÀÖÀ¸¸ç, 2023³â¿¡´Â Æí¸®ÇÏ°í ³Î¸® »ç¿ëµÇ´Â °æ±¸¿ë ¿ÏÇÏÁ¦°¡ °¡Àå ³ôÀº ¼öÀÍÀ» âÃâÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª 2024³âºÎÅÍ 2032³â±îÁöÀÇ ¿¹Ãø ±â°£¿¡´Â Á÷Àå¿ë ¿ÏÇÏÁ¦°¡ °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ Á¦Á¦´Â ƯÁ¤ Áúȯ¿¡ ´ëÇÑ Ç¥Àû Ä¡·á¸¦ Á¦°øÇϱ⠶§¹®¿¡ ÀαⰡ ³ô¾ÆÁú °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ÀûÀÀÁõº° ½ÃÀå ¼¼ºÐÈ­: ¸¸¼º º¯ºñ ÀûÀÀÁõÀº ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù.

¶Ç ´Ù¸¥ Áß¿äÇÑ ¼¼ºÐÈ­ ¿äÀÎÀº ¸¸¼º º¯ºñ, °ú¹Î¼º ´ëÀå ÁõÈıº ¹× ±âŸ·Î ±¸ºÐµÇ´Â ¿ÏÇÏÁ¦ ÀûÀÀÁõÀ¸·Î, 2023³â¿¡´Â ¸¸¼º º¯ºñ ÀûÀÀÁõ¿¡¼­ °¡Àå ³ôÀº ¸ÅÃâÀ» ±â·ÏÇß½À´Ï´Ù. ±×·¯³ª 2024³âºÎÅÍ 2032³â±îÁö ¿¹Ãø ±â°£ µ¿¾È °ú¹Î¼º ´ëÀå ÁõÈıº ÀûÀÀÁõÀº ÀÎÁöµµ¿Í ÀÌÇØµµ°¡ ³ô¾ÆÁü¿¡ µû¶ó °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÏ¹Ì, ¼¼°è ¸®´õÀÇ ÀÚ¸®¸¦ Áö۰í ÀÖ½À´Ï´Ù.

Áö¿ªº°·Î º¸¸é ¿ÏÇÏÁ¦ ½ÃÀåÀº ´Ù¾çÇÑ Ãß¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ºÏ¹Ì´Â 2023³â °¡Àå ³ôÀº ¸ÅÃâ ºñÀ²À» ±â·ÏÇߴµ¥, ÀÌ´Â °Ç°­ Àνİú ¶óÀÌÇÁ½ºÅ¸ÀÏ ¿äÀÎÀ¸·Î ÀÎÇØ °¡Àå ³ôÀº ¸ÅÃâ ºñÀ²À» ±â·ÏÇß½À´Ï´Ù. ±×·¯³ª ¾Æ½Ã¾ÆÅÂÆò¾çÀº ½ÅÈï ½ÃÀå¿¡¼­ À§Àå °Ç°­¿¡ ´ëÇÑ Àνİú ¿ÏÇÏÁ¦¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ ³ô¾ÆÁü¿¡ µû¶ó 2024³âºÎÅÍ 2032³â±îÁö °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå Á¡À¯À² È®´ë¸¦ À§ÇÑ R&D ÅõÀÚ

¿ÏÇÏÁ¦ ½ÃÀå¿¡¼­´Â Bayer AG, GlaxoSmithKline plc, Sanofi, Boehringer Ingelheim Pharmaceuticals Inc. ÀÌµé ±â¾÷ÀÌ Á¦Á¦¸¦ °³¼±ÇÑ ½ÃÀå¿¡¼­ÀÇ Á¸Àç°¨À» È®´ëÇϱâ À§Çؼ­ ²ÙÁØÈ÷ ¿¬±¸°³¹ß¿¡ ÅõÀÚÇØ ¿Ô½À´Ï´Ù. 2023³â¿¡´Â »ó´çÇÑ ¼öÀÍÀ» ±â·ÏÇßÀ¸¸ç, 2024-2032³â¿¡µµ À̵éÀÇ Àü·«Àû ÅõÀÚ·Î ÀÎÇØ ³ôÀº ¼öÀÍÀÌ ¿¹»óµË´Ï´Ù. ÁÖ¿ä Àü·«À¸·Î´Â »õ·Î¿î Á¦Çü µµÀÔ, ºÎµå·´°í È¿°úÀûÀÎ ¼Ö·ç¼ÇÀ» °­Á¶ÇÏ´Â ¸¶ÄÉÆÃ Ä·ÆäÀÎ, À¯Åë¸Á È®´ë µîÀÌ ÀÖ½À´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´äº¯À» ¾òÀ» ¼ö ÀÖ´Â ÁÖ¿ä Áú¹®

¿ÏÇÏÁ¦ ½ÃÀåÀÇ ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ¹Ì½ÃÀû ¹× °Å½ÃÀû ȯ°æ ¿äÀÎÀº ¹«¾ùÀΰ¡?

ÇöÀç ¹× ¿¹Ãø ±â°£ µ¿¾È Á¦Ç° ºÎ¹® ¹× Áö¿ª¿¡ ´ëÇÑ ÁÖ¿ä ÅõÀÚ Æ÷ÄÏÀº ¹«¾ùÀΰ¡?

2032³â±îÁöÀÇ ÃßÁ¤Ä¡ ¹× ½ÃÀå Àü¸Á

¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ CAGRÀ» Â÷ÁöÇÏ´Â ºÎ¹®Àº ¹«¾ùÀΰ¡?

½ÃÀå Á¡À¯À²ÀÌ ³ôÀº ºÎ¹®°ú ±× ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

ÁßÀú¼Òµæ ±¹°¡´Â ¿ÏÇÏÁ¦ ½ÃÀå¿¡ ÅõÀÚÇϰí Àִ°¡?

¿ÏÇÏÁ¦ ½ÃÀå¿¡¼­ °¡Àå ±Ô¸ð°¡ Å« Áö¿ª ½ÃÀåÀº ¾îµðÀΰ¡?

¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« µî ½ÅÈï ½ÃÀå ½ÃÀå µ¿Çâ°ú ¿ªÇÐÀº?

¿ÏÇÏÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä µ¿ÇâÀº ¹«¾ùÀΰ¡?

¼¼°è ¿ÏÇÏÁ¦ ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­Çϱâ À§ÇÑ ÁÖ¿ä °æÀï»ç¿Í ±× Àü·«Àº ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

  • º¸°í¼­ÀÇ ³»¿ë
  • ½ÃÀå ¼¼ºÐÈ­
  • Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¿ÏÇÏÁ¦ ½ÃÀå : °æÀï ºÐ¼®

  • ÁÖ¿ä º¥´õÀÇ ½ÃÀå Æ÷Áö¼Å´×
  • º¥´õ°¡ äÅÃÇÏ´Â Àü·«
  • ÁÖ¿ä »ê¾÷ Àü·«
  • Tier ºÐ¼® : 2023³â vs. 2031³â

Á¦4Àå ¿ÏÇÏÁ¦ ½ÃÀå : ¸ÅÅ©·Î ºÐ¼®°ú ½ÃÀå ¿ªÇÐ

  • ¼­·Ð
  • ¼¼°èÀÇ ¿ÏÇÏÁ¦ ½ÃÀå ¸ÅÃâ, 2021-2031³â
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ÁÖ¿ä °úÁ¦
    • ÁÖ¿ä ±âȸ
  • ¼ºÀå ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎÀÇ ¿µÇ⠺м®
  • See-Saw ºÐ¼®
  • Porter's Five forces ¸ðµ¨
    • °ø±Þ ±â¾÷ÀÇ Èû
    • ±¸¸ÅÀÚÀÇ Èû
    • ´ëüǰÀÇ À§Çù
    • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°è
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû »óȲ
    • °æÁ¦ Á¤¼¼
    • ±â¼ú »óȲ
    • ¹ýÀû »óȲ
    • »çȸÀû »óȲ

Á¦5Àå ¿ÏÇÏÁ¦ ½ÃÀå : Åõ¿© °æ·Îº°, 2022-2032³â

  • ½ÃÀå °³¿ä
  • ¼ºÀå ¹× ¸ÅÃ⠺м® : 2023³â vs. 2031³â
  • ½ÃÀå ¼¼ºÐÈ­
    • °æ±¸
    • Á÷Àå

Á¦6Àå ¿ÏÇÏÁ¦ ½ÃÀå : ÀûÀÀÁõº°, 2022-2032³â

  • ½ÃÀå °³¿ä
  • ¼ºÀå ¹× ¸ÅÃ⠺м® : 2023³â vs. 2031³â
  • ½ÃÀå ¼¼ºÐÈ­
    • ¸¸¼º º¯ºñ
    • °ú¹Î¼º ÀåÁõÈıº
    • ±âŸ

Á¦7Àå ¿ÏÇÏÁ¦ ½ÃÀå : ¾àÁ¦ À¯Çüº°, 2022-2032³â

  • ½ÃÀå °³¿ä
  • ¼ºÀå ¹× ¸ÅÃ⠺м® : 2023³â vs. 2031³â
  • ½ÃÀå ¼¼ºÐÈ­
    • °í»ïÅõ¾Ð
    • ¹úÅ© Çü¼º
    • º¯¿¬È­Á¦
    • À±È°À¯
    • ÀÚ±ØÁ¦

Á¦8Àå ¿ÏÇÏÁ¦ ½ÃÀå : ÃÖÁ¾ ¿ëµµº°, 2022-2032³â

  • ½ÃÀå °³¿ä
  • ¼ºÀå ¹× ¸ÅÃ⠺м® : 2023³â vs. 2031³â
  • ½ÃÀå ¼¼ºÐÈ­
    • º´¿ø ¹× Ŭ¸®´Ð
    • ¿¬±¸±â°ü
    • ±âŸ

Á¦9Àå ºÏ¹ÌÀÇ ¿ÏÇÏÁ¦ ½ÃÀå, 2022-2032³â

  • ½ÃÀå °³¿ä
  • ¿ÏÇÏÁ¦ ½ÃÀå : Åõ¿© °æ·Îº°, 2022-2032³â
  • ¿ÏÇÏÁ¦ ½ÃÀå : ÀûÀÀÁõº°, 2022-2032³â
  • ¿ÏÇÏÁ¦ ½ÃÀå : ¾àÁ¦ À¯Çüº°, 2022-2032³â
  • ¿ÏÇÏÁ¦ ½ÃÀå : ÃÖÁ¾ ¿ëµµº°, 2022-2032³â
  • ¿ÏÇÏÁ¦ ½ÃÀå : Áö¿ªº°, 2022-2032³â
    • ºÏ¹Ì
      • ¹Ì±¹
      • ij³ª´Ù
      • ±âŸ ºÏ¹Ì

Á¦10Àå ¿µ±¹¡¤À¯·´¿¬ÇÕÀÇ ¿ÏÇÏÁ¦ ½ÃÀå, 2022-2032³â

  • ½ÃÀå °³¿ä
  • ¿ÏÇÏÁ¦ ½ÃÀå : Åõ¿© °æ·Îº°, 2022-2032³â
  • ¿ÏÇÏÁ¦ ½ÃÀå : ÀûÀÀÁõº°, 2022-2032³â
  • ¿ÏÇÏÁ¦ ½ÃÀå : ¾àÁ¦ À¯Çüº°, 2022-2032³â
  • ¿ÏÇÏÁ¦ ½ÃÀå : ÃÖÁ¾ ¿ëµµº°, 2022-2032³â
  • ¿ÏÇÏÁ¦ ½ÃÀå : Áö¿ªº°, 2022-2032³â
    • ¿µ±¹¡¤À¯·´¿¬ÇÕ
      • ¿µ±¹
      • µ¶ÀÏ
      • ½ºÆäÀÎ
      • ÀÌÅ»¸®¾Æ
      • ÇÁ¶û½º
      • ±âŸ ¿µ±¹¡¤À¯·´¿¬ÇÕ

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¿ÏÇÏÁ¦ ½ÃÀå, 2022-2032³â

  • ½ÃÀå °³¿ä
  • ¿ÏÇÏÁ¦ ½ÃÀå : Åõ¿© °æ·Îº°, 2022-2032³â
  • ¿ÏÇÏÁ¦ ½ÃÀå : ÀûÀÀÁõº°, 2022-2032³â
  • ¿ÏÇÏÁ¦ ½ÃÀå : ¾àÁ¦ À¯Çüº°, 2022-2032³â
  • ¿ÏÇÏÁ¦ ½ÃÀå : ÃÖÁ¾ ¿ëµµº°, 2022-2032³â
  • ¿ÏÇÏÁ¦ ½ÃÀå : Áö¿ªº°, 2022-2032³â
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
      • Áß±¹
      • ÀϺ»
      • Àεµ
      • È£ÁÖ
      • Çѱ¹
      • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç

Á¦12Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ ¿ÏÇÏÁ¦ ½ÃÀå, 2022-2032³â

  • ½ÃÀå °³¿ä
  • ¿ÏÇÏÁ¦ ½ÃÀå : Åõ¿© °æ·Îº°, 2022-2032³â
  • ¿ÏÇÏÁ¦ ½ÃÀå : ÀûÀÀÁõº°, 2022-2032³â
  • ¿ÏÇÏÁ¦ ½ÃÀå : ¾àÁ¦ À¯Çüº°, 2022-2032³â
  • ¿ÏÇÏÁ¦ ½ÃÀå : ÃÖÁ¾ ¿ëµµº°, 2022-2032³â
  • ¿ÏÇÏÁ¦ ½ÃÀå : Áö¿ªº°, 2022-2032³â
    • ¶óƾ¾Æ¸Þ¸®Ä«
      • ºê¶óÁú
      • ¸ß½ÃÄÚ
      • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«

Á¦13Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¿ÏÇÏÁ¦ ½ÃÀå, 2022-2032³â

  • ½ÃÀå °³¿ä
  • ¿ÏÇÏÁ¦ ½ÃÀå : Åõ¿© °æ·Îº°, 2022-2032³â
  • ¿ÏÇÏÁ¦ ½ÃÀå : ÀûÀÀÁõº°, 2022-2032³â
  • ¿ÏÇÏÁ¦ ½ÃÀå : ¾àÁ¦ À¯Çüº°, 2022-2032³â
  • ¿ÏÇÏÁ¦ ½ÃÀå : ÃÖÁ¾ ¿ëµµº°, 2022-2032³â
  • ¿ÏÇÏÁ¦ ½ÃÀå : Áö¿ªº°, 2022-2032³â
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
      • GCC
      • ¾ÆÇÁ¸®Ä«
      • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦14Àå ±â¾÷ °³¿ä

  • Bayer AG
  • GlaxoSmithKline plc
  • Sanofi
  • Boehringer Ingelheim Pharmaceuticals Inc.
  • Procter & Gamble Company
  • Purdue Pharma
  • Sucampo Pharmaceuticals Inc.
  • ±âŸ ÁÖ¿ä ±â¾÷
LSH 24.01.18

The laxative market plays a crucial role in providing relief from constipation and related gastrointestinal issues. The laxative market is expected to grow at a CAGR of 6.1% during the forecast period of 2024 to 2032, driven by increasing health awareness and changing lifestyles. Looking ahead to the period from 2024 to 2032, the market is expected to continue evolving with advancements in formulations and a broader range of indications. In summary, the laxative market is poised for continued growth, driven by increasing health awareness, changing lifestyles, and advancements in formulations. Potential side effects remain a restraint. Key players are expected to maintain their competitive edge through innovation and customer-centric strategies, with revenues projected to rise from 2023 to 2032.

Increasing Health Awareness

 In 2023, the laxative market witnessed substantial growth due to the increasing health awareness among consumers. More individuals are recognizing the importance of maintaining regular bowel movements for overall well-being. This growing awareness led to higher demand for laxatives as a solution for constipation and other gastrointestinal issues. The emphasis on health is expected to continue as a key driver from 2024 to 2032.

Changing Lifestyles and Dietary Habits

The market was also driven by changing lifestyles and dietary habits. Sedentary lifestyles and poor dietary choices have contributed to an increased prevalence of constipation and related conditions. laxatives became a go-to solution for individuals seeking quick relief. As these lifestyle factors persist, the demand for laxatives is expected to continue growing, contributing to a high CAGR during the forecast period.

Advancements in Formulations

Another significant driver was advancements in laxative formulations. The market witnessed the introduction of more gentle and effective laxatives with reduced side effects. Innovations in oral and rectal formulations improved the user experience, making them more attractive to consumers. As these formulations evolve further, they are expected to drive market growth with a high CAGR from 2024 to 2032.

Restraint in the Laxative Market

Despite its growth, the laxative market faces a restraint related to potential side effects. In 2023, concerns about the potential for dependency and gastrointestinal issues with long-term laxative use acted as a restraint. These side effects are expected to remain a challenge from 2024 to 2032, necessitating efforts to educate consumers on the proper use of laxatives and mitigate potential risks.

Market Segmentation by Route of Administration: Oral laxatives Dominate the Market

The laxative market can be segmented by route of administration into two categories: Oral and Rectal. In 2023, the highest revenue was attributed to oral laxatives, which are convenient and widely used. However, during the forecast period from 2024 to 2032, rectal laxatives are expected to exhibit the highest CAGR. These formulations offer targeted relief for specific cases and are likely to gain popularity.

Market Segmentation by Indication: Chronic Constipation indication Dominates the Market

Another crucial segmentation factor is the indication for laxative use, which can be divided into Chronic Constipation, Irritable Bowel Syndrome, and Others. In 2023, the highest revenue came from the Chronic Constipation indication, as it represents a common and recurring condition. However, during the forecast period from 2024 to 2032, the irritable bowel syndrome indication is expected to exhibit the highest CAGR, as it gains more recognition and understanding.

North America Remains the Global Leader

Geographically, the laxative market exhibits diverse trends. North America recorded the highest revenue percentage in 2023, driven by increased health consciousness and lifestyle factors. However, the Asia-Pacific region is expected to have the highest CAGR from 2024 to 2032, as awareness of gastrointestinal health and accessibility to laxatives grow in emerging markets.

R&D Investment to Enhance the Market Share

The laxative market is characterized by competition among key players, such as Bayer AG, GlaxoSmithKline plc, Sanofi, Boehringer Ingelheim Pharmaceuticals Inc., Procter & Gamble Company, Purdue Pharma, and Sucampo Pharmaceuticals Inc. These companies have consistently invested in research and development to improve laxative formulations and expand their market presence. In 2023, they recorded substantial revenues, and it is expected that their strategic investments will continue to yield high returns from 2024 to 2032. Key strategies include introducing new formulations, marketing campaigns emphasizing gentle and effective solutions, and expanding distribution networks.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofLaxative market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Laxative market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Route of Administration

    • Oral
    • Rectal

Indication

    • Chronic Constipation
    • Irritable Bowel Syndrome
    • Others

Drug Type

    • Hyperosmotic
    • Bulk-Forming
    • Stool Softeners
    • Lubricants
    • Stimulants

End Use

    • Hospitals & Clinics
    • Research Institutes
    • Others

Region Segment (2022-2032; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Laxative market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2032.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Laxative market?

Which is the largest regional market for Laxative market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Laxative market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Laxative market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Laxative Market
  • 2.2. Global Laxative Market, By Route of Administration, 2023 (US$ Million)
  • 2.3. Global Laxative Market, By Indication, 2023 (US$ Million)
  • 2.4. Global Laxative Market, By Drug Type, 2023 (US$ Million)
  • 2.5. Global Laxative Market, By End Use, 2023 (US$ Million)
  • 2.6. Global Laxative Market, By Geography, 2023 (US$ Million)
  • 2.7. Attractive Investment Proposition by Geography, 2023

3. Laxative Market: Competitive Analysis

  • 3.1. Market Positioning of Key Laxative Market Vendors
  • 3.2. Strategies Adopted by Laxative Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2023 Versus 2031

4. Laxative Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Laxative Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis
  • 4.6. Porter's Five Force Model
    • 4.6.1. Supplier Power
    • 4.6.2. Buyer Power
    • 4.6.3. Threat Of Substitutes
    • 4.6.4. Threat Of New Entrants
    • 4.6.5. Competitive Rivalry
  • 4.7. PESTEL Analysis
    • 4.7.1. Political Landscape
    • 4.7.2. Economic Landscape
    • 4.7.3. Technology Landscape
    • 4.7.4. Legal Landscape
    • 4.7.5. Social Landscape

5. Laxative Market: By Route of Administration, 2022-2032, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2023 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. Oral
    • 5.3.2. Rectal

6. Laxative Market: By Indication, 2022-2032, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2023 Versus 2031
  • 6.3. Market Segmentation
    • 6.3.1. Chronic Constipation
    • 6.3.2. Irritable Bowel Syndrome
    • 6.3.3. Others

7. Laxative Market: By Drug Type, 2022-2032, USD (Million)

  • 7.1. Market Overview
  • 7.2. Growth & Revenue Analysis: 2023 Versus 2031
  • 7.3. Market Segmentation
    • 7.3.1. Hyperosmotic
    • 7.3.2. Bulk-Forming
    • 7.3.3. Stool Softeners
    • 7.3.4. Lubricants
    • 7.3.5. Stimulants

8. Laxative Market: By End Use, 2022-2032, USD (Million)

  • 8.1. Market Overview
  • 8.2. Growth & Revenue Analysis: 2023 Versus 2031
  • 8.3. Market Segmentation
    • 8.3.1. Hospitals & Clinics
    • 8.3.2. Research Institutes
    • 8.3.3. Others

9. North America Laxative Market, 2022-2032, USD (Million)

  • 9.1. Market Overview
  • 9.2. Laxative Market: By Route of Administration, 2022-2032, USD (Million)
  • 9.3. Laxative Market: By Indication, 2022-2032, USD (Million)
  • 9.4. Laxative Market: By Drug Type, 2022-2032, USD (Million)
  • 9.5. Laxative Market: By End Use, 2022-2032, USD (Million)
  • 9.6.Laxative Market: By Region, 2022-2032, USD (Million)
    • 9.6.1.North America
      • 9.6.1.1. U.S.
        • 9.6.1.1.1. Laxative Market: By Route of Administration, 2022-2032, USD (Million)
        • 9.6.1.1.2. Laxative Market: By Indication, 2022-2032, USD (Million)
        • 9.6.1.1.3. Laxative Market: By Drug Type, 2022-2032, USD (Million)
        • 9.6.1.1.4. Laxative Market: By End Use, 2022-2032, USD (Million)
      • 9.6.1.2. Canada
        • 9.6.1.2.1. Laxative Market: By Route of Administration, 2022-2032, USD (Million)
        • 9.6.1.2.2. Laxative Market: By Indication, 2022-2032, USD (Million)
        • 9.6.1.2.3. Laxative Market: By Drug Type, 2022-2032, USD (Million)
        • 9.6.1.2.4. Laxative Market: By End Use, 2022-2032, USD (Million)
      • 9.6.1.3. Rest of North America
        • 9.6.1.3.1. Laxative Market: By Route of Administration, 2022-2032, USD (Million)
        • 9.6.1.3.2. Laxative Market: By Indication, 2022-2032, USD (Million)
        • 9.6.1.3.3. Laxative Market: By Drug Type, 2022-2032, USD (Million)
        • 9.6.1.3.4. Laxative Market: By End Use, 2022-2032, USD (Million)

10. UK and European Union Laxative Market, 2022-2032, USD (Million)

  • 10.1. Market Overview
  • 10.2. Laxative Market: By Route of Administration, 2022-2032, USD (Million)
  • 10.3. Laxative Market: By Indication, 2022-2032, USD (Million)
  • 10.4. Laxative Market: By Drug Type, 2022-2032, USD (Million)
  • 10.5. Laxative Market: By End Use, 2022-2032, USD (Million)
  • 10.6.Laxative Market: By Region, 2022-2032, USD (Million)
    • 10.6.1.UK and European Union
      • 10.6.1.1. UK
        • 10.6.1.1.1. Laxative Market: By Route of Administration, 2022-2032, USD (Million)
        • 10.6.1.1.2. Laxative Market: By Indication, 2022-2032, USD (Million)
        • 10.6.1.1.3. Laxative Market: By Drug Type, 2022-2032, USD (Million)
        • 10.6.1.1.4. Laxative Market: By End Use, 2022-2032, USD (Million)
      • 10.6.1.2. Germany
        • 10.6.1.2.1. Laxative Market: By Route of Administration, 2022-2032, USD (Million)
        • 10.6.1.2.2. Laxative Market: By Indication, 2022-2032, USD (Million)
        • 10.6.1.2.3. Laxative Market: By Drug Type, 2022-2032, USD (Million)
        • 10.6.1.2.4. Laxative Market: By End Use, 2022-2032, USD (Million)
      • 10.6.1.3. Spain
        • 10.6.1.3.1. Laxative Market: By Route of Administration, 2022-2032, USD (Million)
        • 10.6.1.3.2. Laxative Market: By Indication, 2022-2032, USD (Million)
        • 10.6.1.3.3. Laxative Market: By Drug Type, 2022-2032, USD (Million)
        • 10.6.1.3.4. Laxative Market: By End Use, 2022-2032, USD (Million)
      • 10.6.1.4. Italy
        • 10.6.1.4.1. Laxative Market: By Route of Administration, 2022-2032, USD (Million)
        • 10.6.1.4.2. Laxative Market: By Indication, 2022-2032, USD (Million)
        • 10.6.1.4.3. Laxative Market: By Drug Type, 2022-2032, USD (Million)
        • 10.6.1.4.4. Laxative Market: By End Use, 2022-2032, USD (Million)
      • 10.6.1.5. France
        • 10.6.1.5.1. Laxative Market: By Route of Administration, 2022-2032, USD (Million)
        • 10.6.1.5.2. Laxative Market: By Indication, 2022-2032, USD (Million)
        • 10.6.1.5.3. Laxative Market: By Drug Type, 2022-2032, USD (Million)
        • 10.6.1.5.4. Laxative Market: By End Use, 2022-2032, USD (Million)
      • 10.6.1.6. Rest of Europe
        • 10.6.1.6.1. Laxative Market: By Route of Administration, 2022-2032, USD (Million)
        • 10.6.1.6.2. Laxative Market: By Indication, 2022-2032, USD (Million)
        • 10.6.1.6.3. Laxative Market: By Drug Type, 2022-2032, USD (Million)
        • 10.6.1.6.4. Laxative Market: By End Use, 2022-2032, USD (Million)

11. Asia Pacific Laxative Market, 2022-2032, USD (Million)

  • 11.1. Market Overview
  • 11.2. Laxative Market: By Route of Administration, 2022-2032, USD (Million)
  • 11.3. Laxative Market: By Indication, 2022-2032, USD (Million)
  • 11.4. Laxative Market: By Drug Type, 2022-2032, USD (Million)
  • 11.5. Laxative Market: By End Use, 2022-2032, USD (Million)
  • 11.6.Laxative Market: By Region, 2022-2032, USD (Million)
    • 11.6.1.Asia Pacific
      • 11.6.1.1. China
        • 11.6.1.1.1. Laxative Market: By Route of Administration, 2022-2032, USD (Million)
        • 11.6.1.1.2. Laxative Market: By Indication, 2022-2032, USD (Million)
        • 11.6.1.1.3. Laxative Market: By Drug Type, 2022-2032, USD (Million)
        • 11.6.1.1.4. Laxative Market: By End Use, 2022-2032, USD (Million)
      • 11.6.1.2. Japan
        • 11.6.1.2.1. Laxative Market: By Route of Administration, 2022-2032, USD (Million)
        • 11.6.1.2.2. Laxative Market: By Indication, 2022-2032, USD (Million)
        • 11.6.1.2.3. Laxative Market: By Drug Type, 2022-2032, USD (Million)
        • 11.6.1.2.4. Laxative Market: By End Use, 2022-2032, USD (Million)
      • 11.6.1.3. India
        • 11.6.1.3.1. Laxative Market: By Route of Administration, 2022-2032, USD (Million)
        • 11.6.1.3.2. Laxative Market: By Indication, 2022-2032, USD (Million)
        • 11.6.1.3.3. Laxative Market: By Drug Type, 2022-2032, USD (Million)
        • 11.6.1.3.4. Laxative Market: By End Use, 2022-2032, USD (Million)
      • 11.6.1.4. Australia
        • 11.6.1.4.1. Laxative Market: By Route of Administration, 2022-2032, USD (Million)
        • 11.6.1.4.2. Laxative Market: By Indication, 2022-2032, USD (Million)
        • 11.6.1.4.3. Laxative Market: By Drug Type, 2022-2032, USD (Million)
        • 11.6.1.4.4. Laxative Market: By End Use, 2022-2032, USD (Million)
      • 11.6.1.5. South Korea
        • 11.6.1.5.1. Laxative Market: By Route of Administration, 2022-2032, USD (Million)
        • 11.6.1.5.2. Laxative Market: By Indication, 2022-2032, USD (Million)
        • 11.6.1.5.3. Laxative Market: By Drug Type, 2022-2032, USD (Million)
        • 11.6.1.5.4. Laxative Market: By End Use, 2022-2032, USD (Million)
      • 11.6.1.6. Rest of Asia Pacific
        • 11.6.1.6.1. Laxative Market: By Route of Administration, 2022-2032, USD (Million)
        • 11.6.1.6.2. Laxative Market: By Indication, 2022-2032, USD (Million)
        • 11.6.1.6.3. Laxative Market: By Drug Type, 2022-2032, USD (Million)
        • 11.6.1.6.4. Laxative Market: By End Use, 2022-2032, USD (Million)

12. Latin America Laxative Market, 2022-2032, USD (Million)

  • 12.1. Market Overview
  • 12.2. Laxative Market: By Route of Administration, 2022-2032, USD (Million)
  • 12.3. Laxative Market: By Indication, 2022-2032, USD (Million)
  • 12.4. Laxative Market: By Drug Type, 2022-2032, USD (Million)
  • 12.5. Laxative Market: By End Use, 2022-2032, USD (Million)
  • 12.6.Laxative Market: By Region, 2022-2032, USD (Million)
    • 12.6.1.Latin America
      • 12.6.1.1. Brazil
        • 12.6.1.1.1. Laxative Market: By Route of Administration, 2022-2032, USD (Million)
        • 12.6.1.1.2. Laxative Market: By Indication, 2022-2032, USD (Million)
        • 12.6.1.1.3. Laxative Market: By Drug Type, 2022-2032, USD (Million)
        • 12.6.1.1.4. Laxative Market: By End Use, 2022-2032, USD (Million)
      • 12.6.1.2. Mexico
        • 12.6.1.2.1. Laxative Market: By Route of Administration, 2022-2032, USD (Million)
        • 12.6.1.2.2. Laxative Market: By Indication, 2022-2032, USD (Million)
        • 12.6.1.2.3. Laxative Market: By Drug Type, 2022-2032, USD (Million)
        • 12.6.1.2.4. Laxative Market: By End Use, 2022-2032, USD (Million)
      • 12.6.1.3. Rest of Latin America
        • 12.6.1.3.1. Laxative Market: By Route of Administration, 2022-2032, USD (Million)
        • 12.6.1.3.2. Laxative Market: By Indication, 2022-2032, USD (Million)
        • 12.6.1.3.3. Laxative Market: By Drug Type, 2022-2032, USD (Million)
        • 12.6.1.3.4. Laxative Market: By End Use, 2022-2032, USD (Million)

13. Middle East and Africa Laxative Market, 2022-2032, USD (Million)

  • 13.1. Market Overview
  • 13.2. Laxative Market: By Route of Administration, 2022-2032, USD (Million)
  • 13.3. Laxative Market: By Indication, 2022-2032, USD (Million)
  • 13.4. Laxative Market: By Drug Type, 2022-2032, USD (Million)
  • 13.5. Laxative Market: By End Use, 2022-2032, USD (Million)
  • 13.6.Laxative Market: By Region, 2022-2032, USD (Million)
    • 13.6.1.Middle East and Africa
      • 13.6.1.1. GCC
        • 13.6.1.1.1. Laxative Market: By Route of Administration, 2022-2032, USD (Million)
        • 13.6.1.1.2. Laxative Market: By Indication, 2022-2032, USD (Million)
        • 13.6.1.1.3. Laxative Market: By Drug Type, 2022-2032, USD (Million)
        • 13.6.1.1.4. Laxative Market: By End Use, 2022-2032, USD (Million)
      • 13.6.1.2. Africa
        • 13.6.1.2.1. Laxative Market: By Route of Administration, 2022-2032, USD (Million)
        • 13.6.1.2.2. Laxative Market: By Indication, 2022-2032, USD (Million)
        • 13.6.1.2.3. Laxative Market: By Drug Type, 2022-2032, USD (Million)
        • 13.6.1.2.4. Laxative Market: By End Use, 2022-2032, USD (Million)
      • 13.6.1.3. Rest of Middle East and Africa
        • 13.6.1.3.1. Laxative Market: By Route of Administration, 2022-2032, USD (Million)
        • 13.6.1.3.2. Laxative Market: By Indication, 2022-2032, USD (Million)
        • 13.6.1.3.3. Laxative Market: By Drug Type, 2022-2032, USD (Million)
        • 13.6.1.3.4. Laxative Market: By End Use, 2022-2032, USD (Million)

14. Company Profile

  • 14.1. Bayer AG
    • 14.1.1. Company Overview
    • 14.1.2. Financial Performance
    • 14.1.3. Product Portfolio
    • 14.1.4. Strategic Initiatives
  • 14.2. GlaxoSmithKline plc
    • 14.2.1. Company Overview
    • 14.2.2. Financial Performance
    • 14.2.3. Product Portfolio
    • 14.2.4. Strategic Initiatives
  • 14.3. Sanofi
    • 14.3.1. Company Overview
    • 14.3.2. Financial Performance
    • 14.3.3. Product Portfolio
    • 14.3.4. Strategic Initiatives
  • 14.4. Boehringer Ingelheim Pharmaceuticals Inc.
    • 14.4.1. Company Overview
    • 14.4.2. Financial Performance
    • 14.4.3. Product Portfolio
    • 14.4.4. Strategic Initiatives
  • 14.5. Procter & Gamble Company
    • 14.5.1. Company Overview
    • 14.5.2. Financial Performance
    • 14.5.3. Product Portfolio
    • 14.5.4. Strategic Initiatives
  • 14.6. Purdue Pharma
    • 14.6.1. Company Overview
    • 14.6.2. Financial Performance
    • 14.6.3. Product Portfolio
    • 14.6.4. Strategic Initiatives
  • 14.7. Sucampo Pharmaceuticals Inc.
    • 14.7.1. Company Overview
    • 14.7.2. Financial Performance
    • 14.7.3. Product Portfolio
    • 14.7.4. Strategic Initiatives
  • 14.8. Other Notable Players
    • 14.8.1. Company Overview
    • 14.8.2. Financial Performance
    • 14.8.3. Product Portfolio
    • 14.8.4. Strategic Initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦